PAST TOP PICK
(A Top Pick Nov 02/21, Down 19%) Good growth internationally. Demand increasing with aging population. Great balance sheet, opportunity to make acquisitions. Trades at 22x. Pandemic backlog of elective surgeries offsets inflationary costs. Supply chain difficulties persist. He'd buy here. Yield is 1.4%.
biotechnology / pharmaceutical

Unlock the latest expert's opinion. Its free

Create a FREE account to see the latest opinions & get alerts about when to buy, sell or hold stocks

Unlock the latest opinion & get signals
HOLD
Medical supply companies impacted by Covid-19, staffing shortages and inflation. Need for healthcare services not going away. Likes business area, but not investing in Stryker. Other companies with better prospects.
biotechnology / pharmaceutical
BUY
Their valuation has declined. Their devices are used in revenue-generating procedures at hospitals, which is safe, even as the economy slows. Good outlook.
biotechnology / pharmaceutical
PAST TOP PICK
(A Top Pick Aug 24/21, Down 23%) It is a medical device company and had a tough time over Covid. Now there is a big backlog in elective surgeries so much more of its products will be needed. 71% of business is from the U.S. where there is lots of room to grow globally. Also doctors doing the surgeries tend to stay with the same products. Lots of free cash flow.
biotechnology / pharmaceutical
BUY
They make medical devices. They bought a medical company focused on hands. Again demographics will increase demand for knee and hip replacements. Also, doctors seldom change device-makers, so they will stick with Stryker. They have little presence outside the U.S. so there are opportunities for growth there. Also, there's a backlog in elective surgeries.
biotechnology / pharmaceutical
PAST TOP PICK
(A Top Pick May 12/21, Down 4%) Elective surgeries shut down due to Covid, so now there's a backlog. Supply chain issues. Employment issues. They can get through these headwinds. Acquisition and integration going well. Digitization being integrated into services, including valuable patient data.
biotechnology / pharmaceutical
HOLD
Robotic-assisted surgery has been a large growth area. Multiple compressed significantly. Elective surgeries accelerating, a positive for the business. Shipping and specialty metal constraints are priced in. Fairly priced. Hold through volatility. Quality company, well run. Look at ROE and ROE growth. Aim for a PE multiple of 21x.
biotechnology / pharmaceutical
PAST TOP PICK
(A Top Pick Apr 06/21, Up 13%) Couple of tough years with Covid. Huge backlog, demographic tailwinds, improve people's quality of life. Pre-eminent company in this area. Can upsell new products coming out.
biotechnology / pharmaceutical
PAST TOP PICK
(A Top Pick Mar 29/21, Up 10%) Company was impacted by Covid-19 (elective procedures reduced). As pandemic recedes, business will improve. Expecting, A&D, further acquisitions and continued growth. Trading at 26x earnings (P/E) which is a fair valuation. Would buy more shares and hold.
biotechnology / pharmaceutical
TOP PICK
Pandemic cancelled elective surgeries, backlog now clearing. Population is aging, and surgeries benefit quality of life. Brand loyalty among physicians. Geographical growth. Recent acquisition will increase digitization of products, which will help patient care. Will see uptick in revenue. Great valuation here. Yield is 1.06%. (Analysts’ price target is $281.30)
biotechnology / pharmaceutical
PAST TOP PICK
(A Top Pick Feb 11/21, Up 4%) Came under pressure, as it's classified higher growth. Still likes their business, as everything in those operating rooms is made by Stryker. Main area of growth is robotic surgery. Wage and cost inflation. Sees perhaps slower capex. Very well run.
biotechnology / pharmaceutical
TOP PICK
73% of their business is in the US plus 21% in developed markets and 6% in emerging, so there's more EM growth to come. Also, elective surgeries were put on hold during Covid, so there's a big backlog to come. Also aging demographics are a tailwind. Also, surgeons remain loyal to their surgical products. (Analysts’ price target is $284.10)
biotechnology / pharmaceutical
PAST TOP PICK
(A Top Pick Oct 02/20, Up 34%) This was recommend before vaccines. This company benefits from elective surgery. These surgeries were not happening then. Expects them to report record earnings in 2021. Better days lie a head. Benefits from the aging population. Has intimate relationships with doctors. It is also a platform that is good at acquiring businesses.
biotechnology / pharmaceutical
PAST TOP PICK
(A Top Pick Sep 14/20, Up 32%) Medical devices are an important place to be. Good acquisition right before the pandemic. Demographic play. Pandemic backlog should ease and improve revenues. Good opportunity globally for next few years.
biotechnology / pharmaceutical
TOP PICK
Has long held this. They produce medical devices for hips, knees and spines. The sector fell off during lockdowns due to no or few elective surgeries, however that is rebounding. Also, this is a demographic play as the population ages and needs such surgeries. Also, doctors stay loyal to a brand of medical devices. Trades at 25x earnings and has $3.7 billion in free cash. (Analysts’ price target is $288.43)
biotechnology / pharmaceutical
Showing 1 to 15 of 124 entries

Stryker Corp.(SYK-N) Rating

Ranking : 4 out of 5

Bullish - Buy Signals / Votes : 8

Neutral - Hold Signals / Votes : 2

Bearish - Sell Signals / Votes : 0

Total Signals / Votes : 10

Stockchase rating for Stryker Corp. is calculated according to the stock experts' signals. A high score means experts mostly recommend to buy the stock while a low score means experts mostly recommend to sell the stock.

Stryker Corp.(SYK-N) Frequently Asked Questions

What is Stryker Corp. stock symbol?

Stryker Corp. is a American stock, trading under the symbol SYK-N on the New York Stock Exchange (SYK). It is usually referred to as NYSE:SYK or SYK-N

Is Stryker Corp. a buy or a sell?

In the last year, 10 stock analysts published opinions about SYK-N. 8 analysts recommended to BUY the stock. 0 analysts recommended to SELL the stock. The latest stock analyst recommendation is . Read the latest stock experts' ratings for Stryker Corp..

Is Stryker Corp. a good investment or a top pick?

Stryker Corp. was recommended as a Top Pick by on . Read the latest stock experts ratings for Stryker Corp..

Why is Stryker Corp. stock dropping?

Earnings reports or recent company news can cause the stock price to drop. Read stock experts’ recommendations for help on deciding if you should buy, sell or hold the stock.

Is Stryker Corp. worth watching?

10 stock analysts on Stockchase covered Stryker Corp. In the last year. It is a trending stock that is worth watching.

What is Stryker Corp. stock price?

On 2022-12-02, Stryker Corp. (SYK-N) stock closed at a price of $243.11.